Whalesbook
Earnings Surge on Robust Demand
Neuland Laboratories reported an exceptional fourth quarter for FY26, with consolidated profit after tax (PAT) surging by 664.7% to ₹212.67 crore, up from ₹27.81 crore in the same period last year. This remarkable profit growth was fueled by a 136.3% year-on-year increase in revenue from operations, which reached ₹776.25 crore in Q4FY26. The company's performance highlights strong demand for its active pharmaceutical ingredients (APIs) and custom manufacturing services.
Full-Year Performance and Dividend Payout
For the fiscal year ended March 31, 2026, Neuland Laboratories saw its revenue climb 37% to ₹2,022.99 crore. Annual profit after tax rose 39.9% to ₹364 crore. Reflecting its strong financial health, the Board of Directors has recommended a final dividend of ₹34 per equity share for FY26, subject to shareholder approval. The record date for this payout is set for July 24, 2026.
Strategic Capacity Expansion
To cater to escalating customer demand, the company has greenlit a significant capacity enhancement project at its Unit-1 facility in Bonthapally Village, Telangana. This expansion will add 120.5 KL capacity over the next 12 to 18 months, involving an investment of approximately ₹143.4 crore. Funding for this strategic move will come from a combination of internal accruals and borrowings.
Global Market Footprint
Neuland Laboratories continues to strengthen its international presence. In Q4FY26, revenue from the USA and North America stood at ₹313.66 crore, with Europe contributing ₹296.61 crore. Domestic revenue from India was recorded at ₹121.50 crore during the quarter. The company also appointed Dr. Mauricio Futran as an Additional Director, bringing over four decades of global pharmaceutical experience.